Mylotarg

Phase 2Small molecule

Pfizer

Mylotarg is one of 27 small molecule programs targeting Leukemia, Myeloid, Acute. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Myeloid, AcuteActive, not recruiting

Acute Promyelocytic LeukemiaRecruiting

Leukemia, Myeloid, AcutePhase 2

Active, not recruiting

Acute Promyelocytic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Leukemia, Myeloid, Acute

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

3 2

Peony

Takeda

Phase 3

1 3

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 4

Bleximenib

Johnson & Johnson

Phase 3

2 5

Cytosar

Teva

Phase 2

2 6

Fludara

Sanofi

Phase 2

1 7

Trexall

Jazz Pharmaceuticals

Phase 2

1 8

Revuforj

SSyndax Pharmaceuticals

Phase 2

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 10

Mylotarg

WWyeth-Lederle Vaccines

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Acute Promyelocytic Leukemia

NCT04793919

Q3 2028

Phase 2Active, not recruiting

Leukemia, Myeloid, Acute

NCT05599360

Clinical

Trials by Indication[1]

Leukemia2 trials

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Completed· Pfizer logo

Pfizer·Phase 4·NCT00304447·30 enrolled

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Completed· Pfizer logo

Pfizer·Phase 2·NCT00044733·38 enrolled

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00195000·43 enrolled

Myelodysplastic Syndrome1 trial

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2/3·NCT00038805·3 enrolled

5 more indications

Relapse1 trial

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Completed·AAcute Leukemia French Association·Phase 1/2·NCT02182596·20 enrolled

CAR1 trial

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Completed· Pfizer logo

Pfizer··NCT00161668·500 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Terminated·VVor Biopharma·Phase 1/2·NCT04849910·67 enrolled

Transplantation1 trial

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Leukemia, Myeloid, Acute1 trial

Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study

Active, not recruiting·SShaare Zedek Medical Center·Phase 2·NCT05599360·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Mylotarg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mylotarg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mylotarg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Mylotarg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Leukemia2 trials

Acute Myeloid Leukemia1 trial

Acute Promyelocytic Leukemia1 trial

MDS1 trial

Myelodysplastic Syndrome1 trial

Relapse1 trial

CAR1 trial

Hematopoietic Stem Cell Transplant1 trial

Transplantation1 trial

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News